Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer

NCT ID: NCT06017557

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

151 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-02

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For the treatment of advanced ovarian cancer, the decision to undergo primary surgery is complex and decided by the surgeon while multiple considering multiple elements. Sometimes, chemotherapy is needed before surgery to shrink some of the tumours. To choose the best patients for primary surgery, several prediction tools have been developed. CT and MRI have most commonly been used to identify sites and amounts of tumors in the abdomen and can help determine if these tumours can be safely removed by surgery. However, these imaging methods are only a prediction, and sometimes a diagnostic laparoscopy (putting a camera in the abdomen to look at all sites of disease) is performed to help this decision process.

With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, the investigators would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumours can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed.

The investigators will enroll patients at a one-time point (being the time of surgery) and follow them forward in time and There will be no additional visits other than the surgery.

During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer Stage III Ovarian Cancer Stage IV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This study focuses on individuals diagnosed or suspected to have Stage III-IV ovarian cancer They must be fit for cytoreductive surgery These individuals also be selected for interval cytoreductive surgery after NACT
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clinical Stage III-IV Ovarian Cancer

individuals who have been diagnosed or are suspected to have Clinical Stage III-IV Ovarian Cancer and CT and MRI have most commonly been used to identify sites and amounts of tumors in the abdomen and can help determine if these tumors can be safely removed by surgery. However, these imaging methods are only a prediction, and sometimes a diagnostic laparoscopy (putting a camera in the abdomen to look at all sites of disease) is performed to help this decision process.

Group Type EXPERIMENTAL

Artificial Intelligence

Intervention Type DIAGNOSTIC_TEST

With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artificial Intelligence

With the introduction of artificial intelligence and machine learning, there is a possibility to create more precise prediction models using images from these diagnostic laparoscopy videos. In particular, it would like to use images from the diagnostic laparoscopy to create machine-learning models to help predict if the tumors can be successfully taken out at primary surgery, or if chemotherapy before surgery would be needed. During surgery time the surgical team takes images however, what makes this different is that these images will be used to help create an algorithm to predict surgical outcomes. These images will be stored in a secure database with an anonymous number not linking these pictures to any of the participants.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients treated at Fondazione Policlinico Gemelli Hospital, Rome Italy, Trillium -Credit Valley Hospital, Mississauga, Ontario and Princess Margaret Cancer Centre, Toronto, Canada
* Patients fit for cytoreductive surgery
* Patients with a primary diagnosis of suspect Stage III-IV ovarian cancer
* Patients selected for interval cytoreductive surgery after NACT

Exclusion Criteria

* Patients with pre-operative Stage I-II disease confined to the pelvis
* Patients unfit for surgery
* Lack of information about patients' surgical outcomes and clinicopathological characteristics
* LGSOC, Clear cell and mucinous, non-epithelial histologic subtypes (if available)
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Fagotti, Prof

Role: PRINCIPAL_INVESTIGATOR

Fondazione Policlinico Universitario A. Gemelli, IRCCS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica

Roma, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Liat Hogen, MD

Role: CONTACT

Phone: 416-946-4501

Email: [email protected]

Ferdous Parveen, MBBS

Role: CONTACT

Phone: 416-946-4501

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anna Fagotti, Prof

Role: primary

Riccardo Oliva

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6854

Identifier Type: -

Identifier Source: org_study_id